Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 3/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475705 | 0.92 | PARP1 (0.49) | CHEK1JAK2AKT1AKT2MAP3K7 | |
| SCHEMBL5470131 | 0.86 | CHEK1 (0.67) | CHEK1KDRPARP1 | |
| SCHEMBL5473206 | 0.85 | CHEK1 (0.52) | CHEK1JAK2MAP3K7KDR | |
| SCHEMBL5465085 | 0.84 | CHEK1 (0.50) | CHEK1JAK2MAP3K7KDR | |
| SCHEMBL5465084 | 0.84 | CHEK1 (0.54) | CHEK1JAK2MAP3K7KDRPARP1 | |
| SCHEMBL5480684 | 0.84 | CHEK1 (0.66) | CHEK1 | |
| SCHEMBL5470117 | 0.83 | CHEK1 (0.53) | CHEK1JAK2JAK1KDRPARP1 | |
| SCHEMBL5475790 | 0.83 | SPHK1 (0.47) | CHEK1 | |
| SCHEMBL5478030 | 0.81 | CHEK1 (0.48) | CHEK1JAK1PARP1 | |
| SCHEMBL5497035 | 0.81 | CHEK1 (0.62) | CHEK1JAK2MAP3K7KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885JAK2 668/4885JAK1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.